Ribon Therapeutics Announces Initiation of Phase Ib/II Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung

Ribon Therapeutics announced the first patient has been dosed in the Phase Ib/II study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung.